Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity 86Y- or 177Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 43, Issue 5, 2016, Pages 925-937

  Cheal, Sarah M ^a   Xu, Hong ^a   Guo, Hong fen ^a   Lee, Sang gyu ^a   Punzalan, Blesida ^a   Chalasani, Sandhya ^a   Fung, Edward K ^a   Jungbluth, Achim ^a   Zanzonico, Pat B ^a   Carrasquillo, Jorge A ^a   O’Donoghue, Joseph ^a   Smith Jones, Peter M ^b   Wittrup, K Dane ^c,d   Cheung, Nai Kong V ^a   Larson, Steven M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c Massachusetts Institute of Technology   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Bispecific antibodies; GPA33; Multistep targeting; Pretargeting; Radioimmunotherapy

Indexed keywords

ANTIBODY CONJUGATE; BISPECIFIC ANTIBODY; DEXTRAN; HAPTEN; IMMUNOGLOBULIN G ANTIBODY; LUTETIUM 177; RADIOPHARMACEUTICAL AGENT; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TETRAXETAN; TUMOR ANTIGEN; YTTRIUM 86; GPA33 PROTEIN, MOUSE; IMMUNOGLOBULIN G; LUTETIUM; MEMBRANE PROTEIN; YTTRIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; CANCER RECURRENCE; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; KIDNEY; LIVER; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; RADIOIMMUNOTHERAPY; SPLEEN; TUMOR XENOGRAFT; ANIMAL; ANTIBODY AFFINITY; COLORECTAL NEOPLASMS; DIAGNOSTIC IMAGING; DRUG SCREENING; IMMUNOLOGY;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODY AFFINITY; COLORECTAL NEOPLASMS; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; LUTETIUM; MEMBRANE GLYCOPROTEINS; MICE; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; SINGLE-CHAIN ANTIBODIES; XENOGRAFT MODEL ANTITUMOR ASSAYS; YTTRIUM RADIOISOTOPES;

EID: 84947906107     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-015-3254-8     Document Type: Article

References (42)

1. American Cancer Society. Colorectal cancer facts & figures 2014–2016. Atlanta: American Cancer Society; 2014.
2. Larson SM, Carrasquillo JA, Cheung NK, Press OW. Radioimmunotherapy of human tumours. Nat Rev Cancer. 2015;15:347–60. doi:10.1038/nrc3925.
3. Hajjar G, Sharkey RM, Burton J, Zhang CH, Yeldell D, Matthies A, et al. Phase I radioimmunotherapy trial with iodine-131-labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer. Clin Colorectal Cancer. 2002;2:31–42. doi:10.3816/CCC.2002.n.009.
4. Wong JYC, Chu DZ, Yamauchi DM, Williams LE, Liu A, Wilczynski S, et al. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. Clin Cancer Res. 2000;6:3855–63.
5. Goldenberg DM, Chang CH, Rossi EA, McBride JW, Sharkey RM. Pretargeted molecular imaging and radioimmunotherapy. Theranostics. 2012;2:523–40. doi:10.7150/thno.3582.
6. Hagan PL, Halpern SE, Dillman RO, Shawler DL, Johnson DE, Chen A, et al. Tumor size: effect on monoclonal antibody uptake in tumor models. J Nucl Med. 1986;27:422–7.
7. Mayer A, Tsiompanou E, Flynn AA, Pedley RB, Dearling J, Boden R, et al. Higher dose and dose-rate in smaller tumors result in improved tumor control. Cancer Invest. 2003;21:382–8.
8. O’Donoghue JA, Smith-Jones PM, Humm JL, Ruan S, Pryma DA, Jungbluth AA, et al. 124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET. J Nucl Med. 2011;52:1878–85. doi:10.2967/jnumed.111.095596.
9. Stillebroer AB, Zegers CM, Boerman OC, Oosterwijk E, Mulders PF, O’Donoghue JA, et al. Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging. J Nucl Med. 2012;53:82–9. doi:10.2967/jnumed.111.094896.
10. O’Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med. 1995;36:1902–9.
11. Reardan DT, Meares CF, Goodwin DA, McTigue M, David GS, Stone MR, et al. Antibodies against metal chelates. Nature. 1985;316:265–8.
12. Goodwin DA, Meares CF, Watanabe N, McTigue M, Chaovapong W, Ransone CM, et al. Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy. Cancer Res. 1994;54:5937–46.
13. Feng X, Pak RH, Kroger LA, Moran JK, DeNardo DG, Meares CF, et al. New anti-Cu-TETA and anti-Y-DOTA monoclonal antibodies for potential use in the pre-targeted delivery of radiopharmaceuticals to tumor. Hybridoma. 1998;17:125–32.
14. Corneillie TM, Whetstone PA, Meares CF. Irreversibly binding anti-metal chelate antibodies: artificial receptors for pretargeting. J Inorg Biochem. 2006;100:882–90. doi:10.1016/j.jinorgbio.2006.01.004.
15. Chmura AJ, Orton MS, Meares CF. Antibodies with infinite affinity. Proc Natl Acad Sci U S A. 2001;98:8480–4. doi:10.1073/pnas.151260298.
16. Orcutt KD, Slusarczyk AL, Cieslewicz M, Ruiz-Yi B, Bhushan KR, Frangioni JV, et al. Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging. Nucl Med Biol. 2011;38:223–33. doi:10.1016/j.nucmedbio.2010.08.013.
17. Orcutt KD, Ackerman ME, Cieslewicz M, Quiroz E, Slusarczyk AL, Frangioni JV, et al. A modular IgG-scFv bispecific antibody topology. Protein Eng Des Sel. 2010;23:221–8. doi:10.1093/protein/gzp077.
18. Cheal SM, Xu H, Guo HF, Zanzonico PB, Larson SM, Cheung NK. Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex. Mol Cancer Ther. 2014;13:1803–12. doi:10.1158/1535-7163.MCT-13-0933.
19. Garinchesa P, Sakamoto J, Welt S, Real F, Rettig W, Old L. Organ-specific expression of the colon cancer antigen A33, a cell surface target for antibody-based therapy. Int J Oncol. 1996;9:465–71.
20. Welt S, Divgi CR, Kemeny N, Finn RD, Scott AM, Graham M, et al. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol. 1994;12:1561–71.
21. King DJ, Antoniw P, Owens RJ, Adair JR, Haines AM, Farnsworth AP, et al. Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy. Br J Cancer. 1995;72:1364–72.
22. Carrasquillo JA, Pandit-Taskar N, O’Donoghue JA, Humm JL, Zanzonico P, Smith-Jones PM, et al. (124)I-huA33 antibody PET of colorectal cancer. J Nucl Med. 2011;52:1173–80. doi:10.2967/jnumed.110.086165.
23. Zanzonico P, Carrasquillo JA, Pandit-Taskar N, O’Donoghue JA, Humm JL, Smith-Jones P, et al. PET-based compartmental modeling of (124)I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer. Eur J Nucl Med Mol Imaging. 2015;42:1700–6. doi:10.1007/s00259-015-3061-2.
24. Erdi YE, Macapinlac H, Larson SM, Erdi AK, Yeung H, Furhang EE, et al. Radiation dose assessment for I-131 therapy of thyroid cancer using I-124 PET imaging. Clin Positron Imaging. 1999;2:41–6.
25. Kolbert KS, Pentlow KS, Pearson JR, Sheikh A, Finn RD, Humm JL, et al. Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software. J Nucl Med. 2007;48:143–9.
26. Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 2013;368:623–32. doi:10.1056/NEJMoa1209288.
27. Barendswaard EC, Humm JL, O’Donoghue JA, Sgouros G, Finn RD, Scott AM, et al. Relative therapeutic efficacy of (125)I- and (131)I-labeled monoclonal antibody A33 in a human colon cancer xenograft. J Nucl Med. 2001;42:1251–6.
28. Ruan S, O’Donoghue JA, Larson SM, Finn RD, Jungbluth A, Welt S, et al. Optimizing the sequence of combination therapy with radiolabeled antibodies and fractionated external beam. J Nucl Med. 2000;41:1905–12.
29. Barendswaard EC, O’Donoghue JA, Larson SM, Tschmelitsch J, Welt S, Finn RD, et al. 131I radioimmunotherapy and fractionated external beam radiotherapy: comparative effectiveness in a human tumor xenograft. J Nucl Med. 1999;40:1764–8.
30. Antoniw P, Farnsworth AP, Turner A, Haines AM, Mountain A, Mackintosh J, et al. Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM). Br J Cancer. 1996;74:513–24.
31. El Emir E, Qureshi U, Dearling JL, Boxer GM, Clatworthy I, Folarin AA, et al. Predicting response to radioimmunotherapy from the tumor microenvironment of colorectal carcinomas. Cancer Res. 2007;67:11896–905. doi:10.1158/0008-5472.CAN-07-2967.
32. Orcutt KD, Rhoden JJ, Ruiz-Yi B, Frangioni JV, Wittrup KD. Effect of small-molecule-binding affinity on tumor uptake in vivo: a systematic study using a pretargeted bispecific antibody. Mol Cancer Ther. 2012;11:1365–72. doi:10.1158/1535-7163.MCT-11-0764.
33. McDevitt MR, Chattopadhyay D, Jaggi JS, Finn RD, Zanzonico PB, Villa C, et al. PET imaging of soluble yttrium-86-labeled carbon nanotubes in mice. PLoS One. 2007;2:e907. doi:10.1371/journal.pone.0000907.
34. Orcutt KD, Nasr KA, Whitehead DG, Frangioni JV, Wittrup KD. Biodistribution and clearance of small molecule hapten chelates for pretargeted radioimmunotherapy. Mol Imaging Biol. 2011;13:215–21. doi:10.1007/s11307-010-0353-6.
35. Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76:S10–9. doi:10.1016/j.ijrobp.2009.07.1754.
36. Beauregard JM, Hofman MS, Pereira JM, Eu P, Hicks RJ. Quantitative (177)Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system. Cancer Imaging. 2011;11:56–66. doi:10.1102/1470-7330.2011.0012.
37. Pentlow KS, Finn RD, Larson SM, Erdi YE, Beattie BJ, Humm JL. Quantitative imaging of yttrium-86 with PET: the occurrence and correction of anomalous apparent activity in high density regions. Clin Positron Imaging. 2000;3:85–90.
38. Beattie BJ, Finn RD, Rowland DJ, Pentlow KS. Quantitative imaging of bromine-76 and yttrium-86 with PET: a method for the removal of spurious activity introduced by cascade gamma rays. Med Phys. 2003;30:2410–23.
39. Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther. 2009;8:2861–71. doi:10.1158/1535-7163.MCT-09-0195.
40. Wittrup KD, Thurber GM, Schmidt MM, Rhoden JJ. Practical theoretic guidance for the design of tumor-targeting agents. Methods Enzymol. 2012;503:255–68. doi:10.1016/B978-0-12-396962-0.00010-0.
41. Yazaki PJ, Lee B, Channappa D, Cheung CW, Crow D, Chea J, et al. A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance. Protein Eng Des Sel. 2013;26:187–93. doi:10.1093/protein/gzs096.
42. Liu G, Hnatowich DJ. A semiempirical model of tumor pretargeting. Bioconjug Chem. 2008;19:2095–104. doi:10.1021/bc8002748.